Project Grant R01CA316570
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $733K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded Weill Medical College of Cornell University $703,423 on a Project Grant (R01CA306020) effective June 1, 2026 under the Cancer Biology Research program (CFDA 93.396). The award funds research to identify molecular targets for mitigating immune-related adverse events (IRAEs) triggered by immunotherapy, particularly immune checkpoint blockade agents used in cancer treatment. IRAEs occur in 20–30 percent of cancer patients receiving these agents, with skin and...
- The National Cancer Institute awarded Weill Medical College of Cornell University $716,183 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate and target co-inhibitory and co-stimulatory molecules in CAR T-cell therapies. The award funds research to overcome clinical barriers in adoptive cell therapies with chimeric antigen receptors, which show promise for cancer treatment but face challenges including insufficient T-cell persistence, antigen escape, and...
- The National Cancer Institute awarded The University of Chicago $602,641 under the Cancer Biology Research program (CFDA 93.396) on June 24, 2026, to investigate immune checkpoint receptor inhibitors and their adverse effects in skin and gut tissues. The funded research explores the mechanisms underlying immune-related adverse events (IRAEs) triggered by checkpoint inhibitor therapies used in cancer treatment. CPIs block inhibitory immune receptors such as PD-1, CTLA-4, LAG-3, TIGIT, and TIM-3...
- The National Cancer Institute awarded Weill Medical College of Cornell University $465,595 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026, to investigate immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapies. The project, titled R21CA307817, addresses a serious complication of CAR T-cell treatment for refractory B-cell malignancies. ICANS manifests as cognitive impairment and cerebral edema and remains poorly understood, limiting...
- The National Cancer Institute awarded Weill Medical College of Cornell University $694,133 on May 14, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how sympathetic nervous system axons control melanoma progression and interact with immune effectors in the tumor microenvironment. The research focuses on defining the role of sympathetic axons in inhibiting melanoma growth through norepinephrine signaling via adrenergic receptors on immune cells, particularly...
- The National Cancer Institute awarded Weill Medical College of Cornell University $435,827 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop autologous lymph node T cells engineered to overcome treatment-resistant lung cancer. The research addresses the limited effectiveness of adoptive T-cell therapy in solid tumors by utilizing polyclonal cohorts of multipotent T cells derived from tumor-draining lymph nodes rather than peripheral blood. Prior work...
- The National Cancer Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Trustees of Columbia University in the City of New York $630,089 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds research to characterize the molecular mechanisms by which the DNA translocase SMARCAL1 suppresses anti-tumor immune responses and to identify other DNA damage response factors that function analogously to...
- The National Cancer Institute awarded Weill Medical College of Cornell University $177,004 on September 2, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support investigator-initiated biomedical research in cancer biology and immunology. The award funds a five-year research project examining age-specific and sex-dependent effects of selective serotonin reuptake inhibitors (SSRIs) on anti-tumor immunity and early-onset colorectal cancer susceptibility. The recipient's research...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $697,131 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate myeloid-stromal interactions that drive immune suppression in colorectal cancer and to evaluate therapeutic strategies targeting these pathways. The research addresses the immunological resistance of microsatellite-stable colorectal cancer to immune checkpoint blockade, particularly in patients with liver metastases. The...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of California Irvine $648,626 on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy. The funded research examines why PD-1 checkpoint inhibitors fail in most cancer patients despite providing durable benefits in approximately 40 percent of patients with metastatic melanoma and...